IRIS
MARTORA, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.213
EU - Europa 2.242
NA - Nord America 1.785
SA - Sud America 533
AF - Africa 74
OC - Oceania 4
Totale 8.851
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 1.804
US - Stati Uniti d'America 1.689
CN - Cina 1.098
RU - Federazione Russa 1.076
DE - Germania 573
VN - Vietnam 482
BR - Brasile 443
HK - Hong Kong 255
IN - India 188
IT - Italia 183
KR - Corea 130
FR - Francia 103
FI - Finlandia 92
JP - Giappone 79
AR - Argentina 45
GB - Regno Unito 45
NL - Olanda 45
MX - Messico 39
BD - Bangladesh 34
CA - Canada 33
ES - Italia 26
IQ - Iraq 25
ZA - Sudafrica 22
UA - Ucraina 20
ID - Indonesia 16
PK - Pakistan 16
AT - Austria 15
EC - Ecuador 15
PH - Filippine 15
PL - Polonia 13
IE - Irlanda 11
TH - Thailandia 11
KE - Kenya 10
MA - Marocco 9
TR - Turchia 9
CI - Costa d'Avorio 7
TW - Taiwan 7
VE - Venezuela 7
CL - Cile 6
DZ - Algeria 6
IL - Israele 6
LT - Lituania 6
OM - Oman 6
RS - Serbia 6
EG - Egitto 5
SE - Svezia 5
UY - Uruguay 5
DO - Repubblica Dominicana 4
JO - Giordania 4
PY - Paraguay 4
BO - Bolivia 3
CO - Colombia 3
EE - Estonia 3
KZ - Kazakistan 3
PA - Panama 3
RO - Romania 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AF - Afghanistan, Repubblica islamica di 2
AL - Albania 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
GH - Ghana 2
GN - Guinea 2
KH - Cambogia 2
KW - Kuwait 2
MR - Mauritania 2
NI - Nicaragua 2
PE - Perù 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
AM - Armenia 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BW - Botswana 1
CH - Svizzera 1
CV - Capo Verde 1
ET - Etiopia 1
GM - Gambi 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
JM - Giamaica 1
KG - Kirghizistan 1
LB - Libano 1
LC - Santa Lucia 1
LU - Lussemburgo 1
Totale 8.839
Salva come PNG Salva come JPEG
Città #
Singapore 970
Hefei 614
San Jose 463
Moscow 282
Hong Kong 245
Santa Clara 212
Ashburn 168
Beijing 168
Ho Chi Minh City 147
Kochi 131
Munich 128
Seoul 122
Hanoi 113
Krefeld 113
Lauterbourg 78
The Dalles 73
Tokyo 71
Los Angeles 60
Helsinki 53
Bad Bellingen 50
São Paulo 47
Naples 40
Redondo Beach 38
Dallas 34
Buffalo 25
New York 24
Da Nang 21
Lappeenranta 20
Council Bluffs 18
Mexico City 18
Milan 18
Chicago 17
Seattle 17
Haiphong 16
Orem 16
Rome 15
Boston 14
Chennai 14
Nuremberg 14
Brooklyn 13
Rio de Janeiro 13
Boardman 12
Dublin 11
Frankfurt am Main 11
Baghdad 10
Belo Horizonte 10
Biên Hòa 10
Turku 10
Atlanta 9
Curitiba 9
Denver 9
Poplar 9
Falkenstein 8
Houston 8
London 8
Montreal 8
Nairobi 8
Warsaw 8
Amsterdam 7
Brasília 7
Campinas 7
Kronberg 7
Phoenix 7
Salvador 7
Toronto 7
Xi'an 7
Bắc Giang 6
Florence 6
Guayaquil 6
Johannesburg 6
Jyväskylä 6
Lahore 6
Paris 6
Porto Alegre 6
Pune 6
Ribeirão Preto 6
Rochdale 6
Vienna 6
Ankara 5
Can Tho 5
Ha Long 5
Hải Dương 5
Manchester 5
Montevideo 5
Mumbai 5
New Delhi 5
Salt Lake City 5
San Francisco 5
Santo André 5
Shanghai 5
Turin 5
Zhengzhou 5
Amman 4
Bengaluru 4
Buenos Aires 4
Cape Town 4
Dhaka 4
Don Benito 4
Düsseldorf 4
Erbil 4
Totale 5.101
Salva come PNG Salva come JPEG
Nome #
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study 394
Effect of Dupilumab on Sexual Desire in Adult Patients with Moderate to Severe Atopic Dermatitis 281
Comprehensive Molecular Analysis of Disease-Related Genes as First-Tier Test for Early Diagnosis, Classification, and Management of Patients Affected by Nonsyndromic Ichthyosis 160
Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting 137
Tattooing and hidradenitis suppurativa: stigmatization and camouflage 131
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience 131
Comment on ‘Anogenital dermatology: challenges in the digital era’ 130
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 128
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256" 127
The use of ChatGPT in the dermatological field: a narrative review 127
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 127
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review 126
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature 123
Management of Psoriasis Patients with Serious Infectious Diseases 123
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 123
Risk Factors for Psoriasis Flares: A Narrative Review 118
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis 116
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review 116
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection 115
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature 112
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19 110
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation 110
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation 109
Oral Minoxidil for Chemotherapy-Induced Alopecia 109
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials 107
Unaddressed Challenges in the Treatment of Cutaneous Melanoma? 107
How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis 106
Airborne allergic contact dermatitis "by proxy" due to budesonide 106
Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a psoriasis patient. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab" 105
Comment on ‘Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine’ 104
Hidradenitis Suppurativa Cancer Risk: A Review of the Literature 104
Dietary intervention in acne management: review of the literature and future prospective 103
Very low-calorie ketogenic diet (VLCKD) in the management of hidradenitis suppurativa (Acne Inversa): an effective and safe tool for improvement of the clinical severity of disease. Results of a pilot study 103
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 103
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 102
Lichen planus following Covid-19 vaccination: a narrative review 101
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities 101
Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study 101
Comment on ‘Permethrin-unresponsive scabies in London, UK: a wake-up call’ 99
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? 99
Guselkumab-induced vitiligo in a patient with psoriatic arthritis 98
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 98
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced 98
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 97
Comment on: “Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination” by Gambichler 97
Reply to 'Omalizumab for the management of refractory aquagenic pruritus' 97
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 96
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab 96
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation 94
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study 94
Climate change and the role of dermatologists: a call to action 91
Effectiveness, Safety, and Long-Term Continuation Rate Analysis of Dupilumab Treatment in Adolescents with Atopic Dermatitis: A Single-Center Real-Life Retrospective Study 91
The role of teledermatology for the long-term management of stable psoriasis treated with biologics: a survey-based study 89
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study 89
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation 88
The Past, the Present and the Future of Teledermatology: A Narrative Review 87
Reply to Borgia et al. Comment on “Marasca et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. J. Clin. Med. 2022, 11, 1511” 85
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes—A Review of the Literature 84
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review 84
Reply to ‘Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa’ by Holgersen et al 84
Comment on 'Development of Chilblains Lesions During the COVID-19 Pandemic is Strongly Associated with Cold Weather: Retrospective Analysis of Patients from a Single Center in the United States' 82
Author Reply to “Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?” by Daungsupawong et al 81
Herpes Zoster and COVID-19 Vaccination: A Narrative Review 80
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report 80
Viral Reactivation Following COVID-19 Vaccination: a review of the current literature 77
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 76
Author Reply to “Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?” by Duff et al 75
An update on the current and emerging pharmacotherapies for basal cell carcinomas 75
ChatGPT and dermatology 73
Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa” 72
ChatGPT and Dermatology: friends or foes? 71
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis 70
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter] 67
Reply to “Dalbavancin for the treatment of severe hidradenitis suppurativa” 66
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study 64
Allergic contact dermatitis to petrolatum: An unknown for patch testing 61
Comment on ‘Eosinophilic pustular folliculitis developing at the site of COVID-19 vaccination’ 61
Advancing Dermatology: Embracing the Power of Artificial Intelligence 60
Management of Advanced Invasive Melanoma: New Strategies 60
Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association 57
Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments 56
ChatGPT and Medical Writing in Dermatology: why should we keep writing? 55
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study 53
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report 52
Comment on “Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review” 51
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient 51
Comment on ‘Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease’ 51
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review 51
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study 50
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? 48
Comment on ‘Oral ivermectin to treat scabies: a comparison of two different regimens’ 47
Guselkumab In A Subset Of Multifailure Patients With Hidradenitis Suppurativa: Real-Word Evidence from Federico II 42
Bimekizumab for Hidradenitis Suppurativa from Trials to Real Life: A Review of the Published Literature 22
Hidradenitis suppurativa and bimekizumab: Looking to the future 20
Reply to 'Rifampicin and clindamycin for epidermal growth factor receptor inhibitor-related acneiform rash' 18
Reply to ‘Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis’ 11
Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study 11
Totale 8.968
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.502
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.502
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202383 0 0 0 0 0 10 11 17 3 16 17 9
2023/2024720 13 22 50 18 11 24 16 42 331 40 77 76
2024/20252.993 104 158 35 31 79 237 288 243 201 398 998 221
2025/20265.172 576 873 637 610 729 200 459 362 471 255 0 0
Totale 8.968